The drug is sometimes prescribed to certain at-risk people—but what does the science say?

Professor David Kerr examines a massive meta-analysis raising questions about GLP-1 drugs and colorectal cancer risk in ...

In a new study, colon cancer patients on these medications were more likely to make it to the 5-year survival mark than patients not on the drugs. In a new study, colon cancer patients who took GLP-1 ...

Add Yahoo as a preferred source to see more of our stories on Google. Ozempic can cost anywhere from over $1,000 to a $25, depending on how you pay for it.Peter Dazeley/Getty Images Colon cancer ...

After getting engaged, the only words journalist Mrinali Dhembla expected to hear were “I do.” Instead, she was told, “You have cancer.” “When I first heard the words, ‘You have cancer,’ I was ...

GLP-1 receptor agonists like Ozempic and Wegovy may increase survival among patients with colon cancer, reported a new study published in Cancer Investigation. GLP-1 receptor agonists were originally ...

Daily aspirin does not reliably prevent bowel cancer in people at average risk, according to a major new review. Any ...

It might be time to rethink that little pill in your medicine cabinet. A new study casts doubt on the idea that regularly ...

Weight-loss drugs have been found to dramatically slash death rates in colon cancer patients, according to new research. Patients taking GLP-1 receptors - the class of drugs behind Ozempic, Wegovy and ...

Nigeria on Wednesday launched its first clinical trial using immunotherapy to treat colorectal cancer, a move doctors say ...

NEW YORK (AP) -- The Food and Drug Administration on Friday approved a new colorectal cancer drug developed by French drugmaker Sanofi and Regeneron Pharmaceuticals Inc. The FDA approved Zaltrap for ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.